NEWS & PRESS

Bladder Cancer: the test that will enable painless follow-up

08/07/2020
Many bladder cancer patients would prefer not to have a cystoscopy - an invasive and painful test - designed to...
READ MORE

Nucleix Announces Publication of Data on Methylation-Based Assay for Detecting High-Risk Non-Muscle Invasive Bladder Cancer in Journal of Clinical Pathology

29/06/2020
Bladder EpiCheck® demonstrated superior performance to cytology alone with high sensitivity, specificity and NPV in a high-risk non-muscle invasive bladder...
READ MORE

Data at 2020 ASCO Virtual Scientific Program Demonstrates Strength of Nucleix’s Six-Marker Methylation-Based Assay Detecting Broad Array of Early Cancers

26/05/2020
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
READ MORE

Israel's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays

19/05/2020
NEW YORK – Israeli liquid biopsy startup Nucleix is taking aim at the US cancer detection market with diagnostic assays...
READ MORE

Nucleix Strengthens Leadership and Expands Footprint for U.S. Growth of Liquid Biopsy Development

11/05/2020
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
READ MORE

STAY UPDATED ON THE LATEST NEWS FROM NUCLEIX!

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !